Oculis Holding Overview
- Status
-
Public
- Employees
-
67
- Stock Symbol
-
OCS
- Investments
-
2
- Share Price
-
$7.64
- (As of Friday Closing)
Oculis Holding General Information
Description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Contact Information
Website
www.oculis.comCorporate Office
- Bahnhofstrasse 20
- 6300 Zug
- Switzerland
Corporate Office
- Bahnhofstrasse 20
- 6300 Zug
- Switzerland
Oculis Holding Timeline
Oculis Holding Stock Performance
As of 13-Nov-2026, Oculis Holding’s stock price is $7.64. Its current market cap is $426M with 55.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.64 | $7.50 | $6.78 - $34.48 | $426M | 55.7M | 267K | -$1.71 |
Oculis Holding Financials Summary
As of 30-Sep-2026, Oculis Holding has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 295,756 | 975,441 | 589,170 | 293,416 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (101,584) | (119,760) | (98,875) | (98,476) |
| Net Income | (101,132) | (119,066) | (97,417) | (98,787) |
| Total Assets | 278,452 | 297,963 | 133,203 | 136,144 |
| Total Debt | 3,339 | 2,921 | 1,306 | 720 |
Oculis Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oculis Holding Comparisons
Industry
Financing
Details
Oculis Holding Competitors (16)
One of Oculis Holding’s 16 competitors is PulseSight Therapeutics, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PulseSight Therapeutics | Venture Capital-Backed | Paris, France | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA |
Oculis Holding Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Oculis Holding Patents
Oculis Holding Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023148231-A1 | Multidose ophthalmic compositions | Inactive | 02-Feb-2022 | ||
| WO-2022003037-A1 | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | Inactive | 30-Jun-2020 | ||
| WO-2021001366-A1 | Method for stabilizing the ph of an aqueous composition comprising a drug | Inactive | 01-Jul-2019 | ||
| JP-2022172291-A | Preparation of cyclodextrin solid complexes for ophthalmic active pharmaceutical ingredient delivery | Active | 29-Nov-2016 | ||
| EP-3548091-A1 | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | Active | 29-Nov-2016 | A61K9/0048 |
Oculis Holding Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Oculis Holding Investments & Acquisitions (2)
Oculis Holding’s most recent deal was a Corporate Asset Purchase with Accure Therapeutics (Worldwide Development and Commercial Rights to Privosegtor in Barcelona, Spain). The deal was made on 10-Aug-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Accure Therapeutics (Worldwide Development and Commercial Rights to Privosegtor in Barcelona, Spain) | 10-Aug-2026 | Corporate Asset Purchase | Buildings and Property | ||
| European Biotech Acquisition | 28-Feb-2023 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Oculis Holding ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Oculis Holding FAQs
-
Where is Oculis Holding headquartered?
Oculis Holding is headquartered in Zug, Switzerland.
-
What is the size of Oculis Holding?
Oculis Holding has 67 total employees.
-
What industry is Oculis Holding in?
Oculis Holding’s primary industry is Drug Discovery.
-
Is Oculis Holding a private or public company?
Oculis Holding is a Public company.
-
What is Oculis Holding’s stock symbol?
The ticker symbol for Oculis Holding is OCS.
-
What is the current stock price of Oculis Holding?
As of 13-Nov-2026 the stock price of Oculis Holding is $7.64.
-
What is the current market cap of Oculis Holding?
The current market capitalization of Oculis Holding is $426M.
-
Who are Oculis Holding’s competitors?
PulseSight Therapeutics, ONL Therapeutics, Sarepta Therapeutics, Foventa Therapeutics, and BioMarin Pharmaceutical are some of the 16 competitors of Oculis Holding.
-
What is Oculis Holding’s annual earnings per share (EPS)?
Oculis Holding’s EPS for 12 months was -$1.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
